ABIONYX Pharma S.A.
ABNX.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | €0 | €0 | €0 | €0 |
| - Cash | €0 | €0 | €0 | €0 |
| + Debt | €0 | €0 | €0 | €0 |
| Enterprise Value | €0 | €0 | €0 | €0 |
| Revenue | €0 | €0 | €0 | €0 |
| % Growth | -0.9% | -11.7% | 678.1% | – |
| Gross Profit | €0 | €0 | €0 | €0 |
| % Margin | 18.3% | 13.3% | 12.1% | 38.4% |
| EBITDA | -€0 | -€0 | -€0 | -€0 |
| % Margin | -107.1% | -104.4% | -76.4% | -1,099% |
| Net Income | -€0 | -€0 | -€0 | -€0 |
| % Margin | -95.7% | -75.8% | -80.1% | -862.5% |
| EPS Diluted | -0.13 | -0.12 | -0.15 | -0.23 |
| % Growth | -8.3% | 20% | 34.8% | – |
| Operating Cash Flow | -€0 | -€0 | -€0 | -€0 |
| Capital Expenditures | €0 | -€0 | -€0 | -€0 |
| Free Cash Flow | -€0 | -€0 | -€0 | -€0 |